Design of mechanism-based inhibitors of transthyretin amyloidosis: Studies with biphenyl ethers and new structural templates

Journal of Medicinal Chemistry

Volumn 50, Issue 23, 2007, Pages 5589-5599

  Gupta, Sarika ^b   Chhibber, Manmohan ^a   Sinha, Sharmistha ^a   Surolia, Avadhesha ^b  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 (5 MERCAPT[1,3,4]OXADIAZOL 2 YL)PHENOL; 2,3,6 TRICHLORO N (4H [1,2,4]TRIAZOL 3 YL); AMYLOID PROTEIN; BIPHENYL DERIVATIVE; ETHER DERIVATIVE; PREALBUMIN; TETRAMER; THYROXINE; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ARTICLE; BINDING SITE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DISSOCIATION CONSTANT; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN AGGREGATION; STRUCTURE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY;

AMYLOIDOSIS; BENZAMIDES; CELL LINE; CELL SURVIVAL; CROSS-LINKING REAGENTS; DRUG DESIGN; FLUORESCENCE; GLUTARAL; HUMANS; KINETICS; MODELS, MOLECULAR; OXADIAZOLES; PHENYL ETHERS; PREALBUMIN; PROTEIN DENATURATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRIAZOLES; TRYPTOPHAN;

EID: 36148961170     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0700159     Document Type: Article

References (58)

1. Kisilevsky, R. Amyloid beta threads in the fabric of Alzheimer's disease. Nat. Med. 1999, 4, 772-773.
2. Harrison, P. M.; Bamborough, P.; Daggett, V.; Prusiner, S. B.; Cohen, F. E. The prion folding problem. Curr. Opin. Struct. Biol. 1997, 7, 53-59.
3. Reese, W.; Hopkovitz, A.; Lifschitz, M. D. B2-microglobulin and associated amyloidosis presenting as bilateral popliteal tumors. Am. J. Kidney Dis. 1988, 12 (4), 323-325.
4. Kelly, J. W. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure 1997, 5, 595-600.
5. Westermark, P.; Wernstedt, C.; Wilander, E.; Hayden, D. W.; O'Brien, T. D.; Johnson, K. H. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 3881-3885.
6. Dabson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 1999, 9, 329-332.
7. Hamilton, J. A.; Benson, M. D. Protein misfolding, evolution and disease. Cell Mol. Life Sci.2000, 58, 1491-1521.
8. Lin Liu Murphy, R. M. Kinetics of Inhibition of β-Amyloid Aggregation by Transthyretin. Biochemistry 2006, 45, 15702-15709.
9. Gustavsson, A.; Jahr, H.; Tobiassen, R.; Jacobson, D. R.; Sletten, K.; Westermark, P. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab. Invest. 1995 73 (5), 703-708.
10. Saraiva, M. J. Transthyretin mutations in health and disease. Hum. Mutat. 1995, 5 (3), 191-196.
11. Vidal, R.; Garzuly, F.; Budka, H.; Lalowski, M.; Linke, R. P.; Brittig, F.; Frangione, B.; Wisniewski, T. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am. J. Pathol. 1996, 148, 361-366.
12. Hammarström, P.; Sekijima, Y.; White, J. P.; Wiseman, R. L.; Lim, A.; Costello, C. E.; Altland, K.; Garzuly, F.; Budka, H.; Kelly, J. W. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 2003, 42, 6656-6663.
13. Quintas, A.; Saraiva, M. J.; Brito, R. M. M. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J. Biol. Chem. 1999, 274, 32943-32949.
14. Jacobson, D. R.; Pastore, R. D.; Yaghoubian, R.; Kane, I.; Gallo, G.; Buck, F. S.; Buxbaum, J. N. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 1997, 336, 466-473.
15. Blake, C. C.; Geisow, M. J.; Oatley, S. J.; Rerat, B.; Rerat, C. F. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J. Mol. Biol. 1978, 121, 339-356.
16. Bartalena, L.; Robbins, J. Thyroid hormone transport proteins. Clin. Lab. Med. 1993, 13, 583-598.
17. Hammarström, P.; Schneider, F.; Kelly, J. W. Trans-suppression of misfolding in an amyloid disease. Science 2001, 293, 2459.
18. Hammarstrom, P.; Wiseman, R. L.; Powers, E. T.; Kelly, J. W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299, 713-716.
19. Morais-de-Sa, E.; Neto-Silva, R. M.; Pereira, P. J.; Saraiva, M. J.; Damas, A. M. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallogr. D Biol. Crystallogr. 2006, 62 (5), 512-519.
20. Morais-de-Sa, E.; Pereira, P. J.; Saraiva, M. J.; Damas, A. M. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. J. Biol. Chem., 2004, 279, 53483-53490.
21. Gales, L.; Macedo-Ribeiro, S.; Arsequell, G.; Valencia, G.; Saraiva, M. J.; Damas, A. M. Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochem. J. 2005, 388, 615-621.
22. Green, N. S.; Foss, T. R.; Kelly, J. W. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 14545-14550.
23. Green, N. S.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J. Am. Chem. Soc. 2003, 125, 13404-13414.
24. Johnson, S. M.; Petrassi, H. M.; Palaninathan, S. K.; Mohamedmohaideen, N. N.; Purkey, H. E.; Nichols, C.; Chiang, K. P.; Walkup, T.; Sacchettini, J. C.; Sharpless, K. B.; Kelly, J. W. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J. Med. Chem. 2005, 48, 1576-1587.
25. Petrassi, H. M.; Johnson, S. M.; Purkey, H. E.; Chiang, K. P.; Walkup, T.; Jiang, X.; Powers, E. T.; Kelly, J. W. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J. Am. Chem. Soc. 2005, 127, 6662-6671.
26. Petrassi, H. M.; Klabunde, T.; Sacchettini, J.; Kelly, J. W. Structure-Based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors. J. Am. Chem. Soc. 2000, 122, 2178-2192.
27. Adamski-Werner, S. L.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem. 2004, 47, 355-374.
28. Almeida, M. R.; Macedo, B.; Cardoso, I.; Alves, I.; Valencia, G.; Arsequell, G.; Planas, A.; Saraiva, M. J. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem. J. 2004, 381, 351-356.
29. Miller, S. R.; Sekijima, Y.; Kelly, J. W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab. Invest. 2004, 84, 545-552.
30. Razavi, H.; Palaninathan, K, S.; Powers, E. T.; Wiseman, R. L.; Purkey, H. E.; Mohamedmohaideen, N. N.; Deechonkit, S.; Chiang, K. P.; Dendle, M. T. A.; Sacchettini, J. C.; Kelly, J. W. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew. Chem. 2003, 42, 2758-2761.
31. Cardoso, I.; Merlini, G.; Saraiva, M. J. 4′-iodo-4′- deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003, 17, 803-809.
32. Sebastiao, M. P.; Merlini, G.; Saraiva, M. J.; Damas, A. M. The molecular interaction of 4′-iodo-4′-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation. Biochem. J. 2000, 351, 273-279.
33. Oza, V. B.; Smith, C.; Raman, P.; Koepf, E. K.; Lashuel, H. A.; Petrassi, H. M.; Chiang, K. P.; Powers, E. T.; Sacchettini, J.; Kelly, J. W. S. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 2002, 45, 321-332.
34. Raghu, P.; Reddy, G. B.; Sivakumar, B. Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization. Arch. Biochem. Biophys. 2002, 400 (1), 43-47.
35. Klabunde, T.; Petrassi, H. M.; Oza, V. B.; Raman, P.; Kelly, J. W.; Sacchettini, J. C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7, 312-321.
36. Peterson, S. A.; Klabunde, T.; Lashuel, H.; Purkey, H.; Sacchettini, J. C.; Kelly, J. W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U.S.A. 1998, 95, 12956-12960.
37. Baures, P. W.; Peterson, S. A.; Kelly, J. W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 1998, 6, 1389-1401.
38. Miroy, G. J.; Lai, Z.; Lashuel, H. A.; Peterson, S. A.; Strang, C.; Kelly, J. W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 15051-15056.
39. Erlanson, D. A.; Hansen, S. K. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly. Curr. Opin. Chem. Biol. 2004, 8, 399-406.
40. Altland, K.; Winter, P.; Saraiva, M. J.; Suhr, O. Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin. Neurogenetics 2004, 5, 61-67.
41. Altland, K.; Winter, P. Potential treatment of transthyretin-type amyloidoses by sulfite. Neurogenetics 1999, 2, 183-188.
42. Dolado, I.; Nieto, J.; Saraiva, M. J.; Arsequell, G.; Valencia, G.; Planas, A. Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors. J. Comb. Chem. 2005, 7, 246-252.
43. Surolia, N.; Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 2001, 7, 167-173.
44. Wojtczak, A.; Cody, V.; Luft, J. R.; Pangborn, W. Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3′,5′-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1996, 52, 758-765.
45. Weisman, L. R.; Johnson, S. M.; Kelker, M. S.; Foss, T.; Wilson, I. A.; Kelly, J. W. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J. Am. Chem. Soc., 2005, 127, 5540-5551.
46. Hurshman, A. R.; White, J. T.; Powers, E. T.; Kelly, J. W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004, 43, 7365-7381.
47. White, J. T.; Kelly, J. W. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3019-3024.
48. Jiang, X.; Buxbaum, J. N.; Kelly, J. W. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 14943-14948.
49. Hammarstrom, P.; Jiang, X.; Hurshman, A. R.; Powers, E. T.; Kelly, J. W. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 16427-16432.
50. Reixach, N.; Deechongkit, S.; Jiang, X.; Kelly, J. W.; Buxbaum, J. N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 2817-2822.
51. Sousa, M. M.; Cardoso, I.; Fernandes, R.; Guimaraes, A.; Saraiva, M. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. J. Am. J. Pathol. 2001, 159, 1993-2000.
52. Chhibber, M.; Kumar, G.; Parasuraman, P.; Ramya, T. N.; Surolia, N.; Surolia, A. Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Bioorg. Med. Chem. 2006, 14 (23), 8086-8098.
53. Lashuel, H. A.; Wurth, C.; Woo, L.; Kelly, J. W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 1999, 38 (41), 13560-135revised73.
54. Klunk, W. E.; Jacob, R. F.; Mason, R. P. Quantifying amyloid by Congo red spectral shift assay. Methods Enzymol. 1999, 309, 285-3005.
55. Le Vine, H. Quantification of β-Sheet Amyloid Fibril Structures with Thioflavin T. Methods Enzymol. 1999, 309, 274-284.
56. Colon, W.; Kelly, J. W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992, 31, 8654-8660.
57. Surolia, I.; Reddy, G. B.; Sinha, S. Hierarchy and the mechanism of fibril formation in ADan peptides. J. Neurochem.2006, 99, 537-548.
58. Sorokine, A.; Prilusky, J.; Abola, E. E.; Edelman, M. Automated analysis of interatomic contacts in proteins. Bioinformatics 1999, 15, 327-332.